Compile Data Set for Download or QSAR
Report error Found 145 Enz. Inhib. hit(s) with all data for entry = 10768
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM566504((S)-4-((2-ethoxyethyl) (4-(5,6,7,8-tetrahydro-1,8-...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465267(US10793564, Compound 56 | US11560376, Compound 56 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465264(US10793564, Compound 53 | US11560376, Compound 53 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465265(US10793564, Compound 54 | US11560376, Compound 54 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465270(US10793564, Compound 59 | US11560376, Compound 59 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465271(US10793564, Compound 60 | US11560376, Compound 60 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465268(US10793564, Compound 57 | US11560376, Compound 57 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465269(US10793564, Compound 58 | US11560376, Compound 58 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465274(US10793564, Compound 63 | US11560376, Compound 63 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465275(US10793564, Compound 64 | US11560376, Compound 64 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465272(US10793564, Compound 61 | US11560376, Compound 61 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465273(US10793564, Compound 62 | US11560376, Compound 62 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465278(US10793564, Compound 67 | US11560376, Compound 67 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465279(US10793564, Compound 68 | US11560376, Compound 68 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465276(US10793564, Compound 65 | US11560376, Compound 65 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465277(US10793564, Compound 66 | US11560376, Compound 66 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465250(US10793564, Compound 39 | US11560376, Compound 39 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465251(US10793564, Compound 40 | US11560376, Compound 40 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465249(US10793564, Compound 38 | US11560376, Compound 38 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465254(US10793564, Compound 43 | US11560376, Compound 43 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465255(US10793564, Compound 44 | US11560376, Compound 44 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465252(US10793564, Compound 41 | US11560376, Compound 41 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465253(US10793564, Compound 42 | US11560376, Compound 42 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465258(US10793564, Compound 47 | US11560376, Compound 47 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465259(US10793564, Compound 48 | US11560376, Compound 48 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465256(US10793564, Compound 45 | US11560376, Compound 45 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465257(US10793564, Compound 46 | US11560376, Compound 46 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465262(US10793564, Compound 51 | US11560376, Compound 51 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465263(US10793564, Compound 52 | US11560376, Compound 52 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465260(US10793564, Compound 49 | US11560376, Compound 49 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465261(US10793564, Compound 50 | US11560376, Compound 50 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465302(US10793564, Compound 91 | US11560376, Compound 91 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465300(US10793564, Compound 89 | US11560376, Compound 89 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465301(US10793564, Compound 90 | US11560376, Compound 90 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465304(US10793564, Compound 93 | US11560376, Compound 93 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465305(US10793564, Compound 94 | US11560376, Compound 94 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465311(US10793564, Compound 100 | US11560376, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465282(US10793564, Compound 71 | US11560376, Compound 71 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465283(US10793564, Compound 72 | US11560376, Compound 72 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465280(US10793564, Compound 69 | US11560376, Compound 69 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465281(US10793564, Compound 70 | US11560376, Compound 70 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465286(US10793564, Compound 75 | US11560376, Compound 75 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465287(US10793564, Compound 76 | US11560376, Compound 76 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465284(US10793564, Compound 73 | US11560376, Compound 73 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465285(US10793564, Compound 74 | US11560376, Compound 74 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465290(US10793564, Compound 79 | US11560376, Compound 79 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465291(US10793564, Compound 80 | US11560376, Compound 80 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465288(US10793564, Compound 77 | US11560376, Compound 77 ...)
Affinity DataIC50: 50nMAssay Description:A third series of exemplary compounds was selected for testing in the solid phase integrin αvβ6 binding assay. The compounds tested were co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465289(US10793564, Compound 78 | US11560376, Compound 78 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 μg/mL) in PBS (100 μL/well 25° C., overnight). The coating soluti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent

Displayed 1 to 50 (of 145 total ) | Next | Last >>
Jump to: